Clinical trial · Observational
New Approach of Assessing Drug Response for Treatment of Nasopharyngeal Cancer
Prospective Evaluation of Plasma EBV DNA Half-life and PET-CT Scanning as a New Tool in Assessing Early Response to Chemotherapy in Patients With Advanced Nasopharyngeal Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The combination of pEBV DNA (half-life) and PET-CT following 1 course of chemotherapy allow earlier and more detection of drug response in advanced NPC than RECIST method, in patients with previously untreated advanced NPC who will receive platinum-based chemotherapy. This study will also determine if this new method can predict survival in these patients. This study may have far-reaching impact on drug development in NPC as it may offer a more optimal way of evaluating drug efficacy in clinical trials and also in clinical management.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chemotherapy | Drug | Chemotherapy | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- advanced nasopharyngeal carcinoma
- interventionNames
- Drug: Chemotherapy
Primary outcomes (2)
- measure
- To determine if measuring tumor metabolic response during chemotherapy can predict survival
- timeFrame
- 3 years
- measure
- To determine if measuring plasma EBV DNA (half-life) early during chemotherapy can predict survival
- timeFrame
- 3 years
Secondary outcomes (4)
- measure
- New method of assessing drug response (measuring tumor metabolic response via FDG-PET & plasma EBV DNA (half-life) after 1 course of chemotherapy) can better predict survival, than the conventional method
- timeFrame
- 3 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * undergo chemotherapy for any one of the following settings: 1. Setting 1: Neoadjuvant chemotherapy prior to cheom-RT 2. Setting 2: Palliative chemotherapy in Chemonaive patients 3. Setting 3: Palliative chemotherapy in previously treated patients (i.e. 2nd line or 3rd line chemo) * Age \>= 18 years * (ECOG) performance status of 0-2 * have detectable levels of pEBV DNA at baseline * have measurable tumor sites by RECIST criteria * have adequate bone marrow, renal and hepatic functions
References
Publications (1)
- DERIVEDMa B, Hui EP, King A, Leung SF, Kam MK, Mo F, Li L, Wang K, Loong H, Wong A, Chan CM, Chan KCA, Wong SCC, Lo YMD, Chan AT. Prospective evaluation of plasma Epstein-Barr virus DNA clearance and fluorodeoxyglucose positron emission scan in assessing early response to chemotherapy in patients with advanced or recurrent nasopharyngeal carcinoma. Br J Cancer. 2018 Apr;118(8):1051-1055. doi: 10.1038/s41416-018-0026-9. Epub 2018 Mar 20. PMID 29555989